A retrospective cohort study identified incident renal and cardiac diagnoses as clinical red flags that predict progression to systemic light chain amyloidosis among patients with precursor monoclonal gammopathy. Investigators focused on newly emerging diagnoses—especially conditions affecting kidney function and cardiac presentation—as strong indicators of future amyloid transformation. The work underscores that progression risk may be captured not only through laboratory biomarkers but also through clinical events. For monitoring and decision-making in precursor populations, the findings support integrating structured surveillance for renal and cardiac changes into progression algorithms.